COST ANALYSIS OF TAXANE-BASED AND CISPLATIN-BASED CHEMOTHERAPY REGIMENS FOR EPITHELIAL OVARIAN CANCER IN DHARMAIS NATIONAL CANCER HOSPITAL


Bambang Dwipoyono, Septyana Choirunisa, Mardiati Nadjib, Amal C Sjaaf

Abstract


Objective: This exploratory study aimed to evaluate and compare the treatment costs of taxane-based versus cisplatin-based chemotherapy.
Methods: This study used data from the medical and financial records of ovarian cancer patients who were admitted to Dharmais National
Cancer Hospital (RSKD) between 2008 and 2012 and subsequently underwent surgery and were treated with chemotherapy. Data were analyzed
using descriptive analysis, and a Kaplan–Meier graph was plotted to compare the survival of the patients in the taxane-based and cisplatin-based
chemotherapy groups.
Results: Of 41 patients, treatment costs were available for nine patients who had undergone taxane-based chemotherapy and for 31 patients who had
undergone cisplatin-based chemotherapy. In general, surgical procedures accounted for the highest proportion of the treatment costs, followed by
chemotherapy. Taxane-based chemotherapy (six cycles) was 4 times more expensive than cisplatin-based therapy. The pre- and post-chemotherapy
costs of care among those treated with the taxane-based regimen were 3-4 times more expensive than those of the patients who received cisplatinbased
treatment. The disease-free recurrence duration of the patients treated with taxane was longer (median=18 months) than that of the patients
treated with cisplatin (median=5 months).
Conclusions: Taxane-based therapy increased the disease-free recurrence duration of the patients, with disease-free recurrence 3 times longer than
that of the patients treated with the cisplatin-based regimen. However, the treatment costs of the taxane-based regimen were 4 times higher than
those of the cisplatin-based treatment.


Keywords


Ovarian cancer, Cost analysis, Taxane chemotherapy, Cisplatin chemotherapy.

| PDF |

References


Kurman RJ, Shih IeM. the origin and pathogenesis of epithelial

ovarian cancer: A proposed unifying theory. Am J Surg Pathol

;34(3):433‑43.

Jelovac D, Armstrong DK. Recent progress in the diagnosis and

treatment of ovarian cancer. CA Cancer J Clin 2011;61(3):183-203.

Hollis RL, Gourley C. Genetic and molecular changes in ovarian

cancer. Cancer Biol Med 2016;13(2):236-47.

Parkin DM, Pisani P, Ferlay J. Global Cancer Statistics. CA Cancer J

Clin 1999;49(1):33-64.

Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer

incidence, mortality and prevalence worldwide. Lyon: IARC

Press;2004.

Aziz MF. Gynecological cancer in Indonesia. J Gynecol Oncol

;20(1):8-10.

Ubiet JF. Angka kesintasan kanker ovarium di RS Kanker Dharmais.

Thesis. Depok: Universitas Indonesia;2009. [In Indonesia].

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D,

Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared

with cisplatin and paclitaxel in patients with optimally resected stage III

ovarian cancer. J Clin Oncol 2003;21(7):3194-200.

Prat A, parera M, Del Campo JM. Prognostic role of CA-125 nadir in

stage IV epithelial ovarian cancer. J Clin Oncol 2008;26(10):1771-2.

Inciura A, Simavicius A, Juozaityte E, Kurtinaitis J, Nadisauskiene R,

Svedas E, et al. Comparison of adjuvant and neoadjuvant chemotherapy

in the management of advanced ovarian cancer: A retrospective study

of 574 patients. BMC cancer 2006;6(1):153.

Cristea M, Han E, Salmon L, Morgan RJ. Review: Practical

considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol

;2(3):175-87.

Rumah Sakit Kanker Dharmais. Gynaecological cancer protocol.

Jakarta: RSKD; 2001. [In Indonesia].

Reeder CE, Gordon D. Managing oncology costs. Am J Manag Care

;12(1 Suppl):S3-16.

Expósito J, Hernández J, Feijóo AF, Nieto T, Briones E. New

chemotherapy treatments in advanced cancer patients an easily

applicable evaluation of clinical efficacy and cost-effectiveness. Acta

Oncol 2003;42(8):895-902.

Sfakianos GP, Havrilesky LJ. A review of cost-effectiveness studies in

ovarian cancer. Cancer Control 2011;18(1):59-64.

Cella D, Peterman A, Hudgens S, Webster K, Socinski MA.

Measuring the side effects of taxane therapy in oncology. Cancer

;98:822-31.

Smith LH. Early clinical detection of ovarian cancer: A review of the

evidence. Expert Rev Anticancer Ther 2006;6(7):1045-52.

McGuire III WP, Markman M. Primary ovarian cancer chemotherapy:

Current standards of care. Br J Cancer 2003;89(Suppl 3):S3-8.




About this article

Title

COST ANALYSIS OF TAXANE-BASED AND CISPLATIN-BASED CHEMOTHERAPY REGIMENS FOR EPITHELIAL OVARIAN CANCER IN DHARMAIS NATIONAL CANCER HOSPITAL

Keywords

Ovarian cancer, Cost analysis, Taxane chemotherapy, Cisplatin chemotherapy.

DOI

10.22159/ijap.2017.v9s1.82_89

Date

30-10-2017

Additional Links

Manuscript Submission

Journal

International Journal of Applied Pharmaceutics
Vol. 9, Special Issue (Oct.), 2017 [PTMDS 2017] Page: 172-175

Online ISSN

0975-7058

Statistics

9 Views | 19 Downloads

Authors & Affiliations

Bambang Dwipoyono
Department of Obstetrics and Gynecology, Dharmais National Cancer Hospital, Jakarta, Indonesia.
Indonesia

Septyana Choirunisa
Department of Pharmacy, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.
Indonesia

Mardiati Nadjib
Department of Health Policy and Administration, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.
Indonesia

Amal C Sjaaf
Department of Health Policy and Administration, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.
Indonesia


Refbacks

  • There are currently no refbacks.